Price Disclosures

Colorado Disclosure Act

Colo. Rev. Stat. § 12-280-308 requires pharmaceutical manufacturers, when engaging in prescription drug marketing, to provide the wholesale acquisition cost (WAC) of the drug to Colorado prescribers. Under Colorado law, the names of generic prescription drugs (if available) from the same therapeutic class (i.e., same or similar mechanism of action used to treat a specific condition) shall also be provided.

Colorado Price Disclosure .pdf

Connecticut Disclosure Act

Connecticut Public Act No. 23-171 requires the disclosure of the list price of a legend drug when a pharmaceutical representative provides information concerning such legend drug to prescribing practitioners or pharmacists, based on the dose and quantity of such legend drug as described in the medication package insert.

Connecticut Price Disclosure .pdf

Vermont Disclosure Act

Vermont law 33 V.S.A. §2005a mandates that pharmaceutical manufacturers disclose to Vermont physicians and other prescribers the average wholesale price (AWP) of drugs they market within the state as well as the prices of other drugs in the same therapeutic class. Under Vermont law, "therapeutic class" is defined as the therapeutic class listed in the 2004 American Hospital Formulary Service Pharmacologic-Therapeutic Classification published by the American Society of Health System Pharmacists (available at https://www.ashp.org).

Information for Vermont Prescribers of Prescription Drugs_Short Form_2025 .pdf

Information for Vermont Prescribers of Prescription Drugs_Long Form_2025 .pdf

IMPORTANT SAFETY INFORMATION

Contraindications

RAPIBLYK^TM is contraindicated in patients with:

Severe sinus bradycardia, sick sinus syndrome, heart block greater than first degree
Decompensated heart failure
Cardiogenic shock
Pulmonary hypertension
Hypersensitivity reactions to RAPIBLYK^TM or any of the inactive ingredients

Warning and Precautions

Hypotension: Patients with hemodynamic compromise, hypovolemia, or on interacting medications are at increased risk of hypotension.
Bradycardia: Patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders are at increased risk of bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest.
Cardiac Failure: Beta-blockers, like RAPIBLYK^TM, can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock.
Reactive Airways Disease: Patients with reactive airways disease should, in general, not receive Beta blockers. Because of its relative beta-1 selectivity and titratability, RAPIBLYK^TM injection may be titrated to the lowest possible effective dose.
Patients with Diabetes Mellitus and Hypoglycemia: beta blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus, patients who are fasting, or children.
Infusion Site Reactions: Infusion site reactions such as pain, swelling and erythema have occurred with the use of RAPIBLYK^TM.
Patients with Prinzmetal’s Angina: beta blockers may exacerbate anginal attacks.
Patients with Pheochromocytoma: Administration of RAPIBLYK without opposing alpha blockade in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure from the attenuation of beta receptor-mediated vasodilation in skeletal muscle.
Patients with Peripheral Circulatory Disorders: RAPIBLYK^TM may exacerbate peripheral circulatory disorders, such as Raynaud’s disease or syndrome, and peripheral occlusive vascular disease.
Abrupt Discontinuation of RAPIBLYK Injection: Severe exacerbations of angina, myocardial infarction, and ventricular arrhythmias have been reported in patients with coronary artery disease upon abrupt discontinuation of beta-blocker therapy.
Hyperkalemia: Beta-blockers, including RAPIBLYK^TM, can cause increases in serum potassium and hyperkalemia. The risk is increased in patients with risk factors such as renal impairment.
Patients with Metabolic Acidosis: Beta-blockers have been reported to cause hyperkalemic renal tubular acidosis.
Patients with Hyperthyroidism: Beta-adrenergic blockade may mask certain clinical signs of hyperthyroidism.
Patients at Risk of Severe Acute Hypersensitivity Reactions: may be more reactive to allergen exposure. Patients using beta blockers may be unresponsive to the usual doses of epinephrine used to treat anaphylactic or anaphylactoid reactions.

Adverse Reactions

The most important and common adverse reaction is hypotension, which in clinical trials occurred in 9.9% of patients receiving RAPIBLYK^TMvs. 1% in those receiving placebo.

Please see the full Prescribing Information for RAPIBLYK^TM at